Omnicell, Inc. · NASDAQ:OMCL
Omnicell — Merger or Acquisition (December 2021)
9 slides from Omnicell's merger presentation, Dec 2, 2021
Slide 1: ReCept
ReCept December 2, 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement 2© 2021 Omnicell, Inc. Content is confidential and proprietary. This presentation contains forward-looking statements that involve risks and uncertainties, including statements regarding the timing and outcome of the acquisition or its consummation, the expected benefits of the
Slide 3: Compelling Strategic Benefits
Compelling Strategic Benefits 3© 2021 Omnicell, Inc. Content is confidential and proprietary. Assists health systems in providing specialty pharmacy services to patients, designed to improve continuity of care and patient outcomes Services complementary to 340B and EnlivenHealth™ as well as IV Compo
Slide 4: ReCept Business at a Glance
ReCept Business at a Glance 4© 2021 Omnicell, Inc. Content is confidential and proprietary. Tech-Enabled Services Model Improves pharmacy cash flow and profitability by monitoring and reconciling third-party collections and remittances for all Rx claims. Efficiently manages collection and distributi
Slide 5: Specialty Pharmacy Macro Trends
Specialty Pharmacy 5© 2021 Omnicell, Inc. Content is confidential and proprietary. Macro Trends Over 50% of current drug spend is in specialty pharmaceuticals.1 Specialty medications account for 75 percent of the approximately 7,000 prescription drugs currently in development, and nearly two- thirds
Slide 6: Specialty Pharmacy Is a Growth Market
6 Specialty Pharmacy Is a Growth Market © 2021 Omnicell, Inc. Content is confidential and proprietary. U S Sp ec ia lty P ha rm a Sa le s ($ B) 162 179 196 219 245 269 293 316 339 365 391 38% 40% 43% 45% 48% 51% 53% 56% 58% 61% 63% 0% 10% 20% 30% 40% 50% 60% 70% 0 50 100 150 200 250 300 350 400 450
Slide 7: Transaction Overview
Transaction Overview 7© 2021 Omnicell, Inc. Content is confidential and proprietary. $100 million in cash, subject to customary adjustments Cash on hand Transaction Consideration Earnings Impact and Returns Sources of Financing Anticipated high growth tech-enabled services business with recurring re
Slide 8: Summary
Summary 8© 2021 Omnicell, Inc. Content is confidential and proprietary. Strong strategic fit for Omnicell Large and attractive growth market Strong specialty pharmacy capabilities Compelling solution that adds to the portfolio of Omnicell products and services intended to meet the critical needs of
Slide 9: Slide 9